US Patent Issued on March 31 for "Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-Beta-TrCP interaction for use in the treatment of fatty liver disease" (Spanish Inventors)

Posted On: 2026-03-31

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,100, issued on March 31.

"Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-Beta-TrCP interaction for use in the treatment of fatty liver disease" was invented by Antonio Cuadrado Pastor (Madrid), Raquel Fernandez Gines (Madrid), Jose Antonio Encinar (Elche, Spain), Rafael Leon Martinez (Madrid), Juan Felipe Franco Gonzalez (Madrid), Manuela Garcia Lopez (Madrid), Maria Isabel Rodriguez Franco (Madrid) and Ana Isabel Rojo Sanchis (Madrid).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to NRF2-BetaTrCP interaction inhibitors with general formula I and its derivate salts for use in the treatment of NR...

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

US Patent Issued on March 31 for "Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-Beta-TrCP interaction for use in the treatment of fatty liver disease" (Spanish Inventors)